AU2013202865B2 - Increase of immune response and targeting by antigens and/or drug linkage - Google Patents

Abstract

H:\aar\lioenoven\NRPoribi\DCC\AAR\505385_ 1.DOC-8/04/2013 26b The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to target drug to CD1d restricted cells.

Description

1 Increase of immune response and targeting by antigens and/or drug linkage This application is a divisional of Australian Apilication No.2008324118, the entire contents of which are incorporated herein by reference. The present invention relates to NKT cell activating glycolipids covalently bound to antigens and/or drug. The present invention relates to compounds consisting of glycolipids covalently bound to an antigen or a drug via a linker. The said compounds are able to induce a stronger immune response than a composition comprising separated glycolipids and antigen. The said compounds are also able to-target drug to CD1d restricted cells. Natural killer T cells ("NKT cells") are a population of innate-like memory/effector cells that express both natural killer (NK) receptors and a conserved, semi-invariant T cell receptor (TCR). NKT cells have been implicated in suppression of autoimmunity and graft rejection, promotion of resistance to pathogens, and promotion of tumor immunity. NKT cells respond with vigorous cytokine production within hours of TCR activation by releasing TH1-type cytokines, including IFN-y and TNF, as well as TH2-type cytokines, including IL-4 and IL-13. The modulation of these lymphokine responses is the major intended effect of adjuvants used in immunogenic compositions. NKT cells recognize foreign and self lipid antigens presented by the CD1d member of the family pf p2 microglobulin-associated molecules. A variety of lipids with different structures have been shown to bind CD1d molecules in a unique manner that accommodates a fatty a cid chain in each of the two hydrophobic binding pockets (A' and F) of the CD1d molecule. Lipid species capable of binding CD1d molecules include mycolic acids, diacylglycerols, sphingolipids, polyisoprenoids, lipopeptides, phosphomycoketides and small hydrophobic compounds. A number of natural and synthetic lipid molecules are processed by antigen presenting cells and presented by CD1 molecules to NKT cells. The prototypical compound used to study NKT cell activation in vitro and in vivo is KRN7000, and a-galactosyceramide ("aGalCer") derived from marine sponge Agelas mauritianus. Additional compounds recently identified include isoglobotrihexosylceramide ("iGB3") which is an endogenous glycolipid which was described in the PCT patent WO 2009/060086 PCT/EP2008/065179 2 application W02006/029010, and PBS-57, a modified 6"amino 6"deoxygalactosyceramide, which was described in PCT application PCT/US2007/066250, incorporated herein by reference. These compounds activate NKT cells and upregulate cytokine responses in vitro and in vivo. 5 Accordingly, it has been proposed to use such compounds as adjuvant to improve vaccine efficacy when co-administered with an antigen (PCT patent application W02006/083671). In the context of vaccination, the antigen has to be presented by an antigen presenting cell (APC), in particular dendritic cells (DCs), to the conventional CD8+ 10 and CD4+ T cells through MHC class I or class il molecules respectively in order to induce a specific immune response towards this antigen. To this purpose, a reciprocal activation of NKT cells and dendritic cells is initiated upon the presentation of cx-galactosylceramides by resting dendritic cells to NKT cells, inducing NKT cells to up-regulate CD40L and Th1 and Th2 cytokines and 15 chemokines. Then CD40 cross-linking induces dendritic cells to upregulate CD40, B7.1 and B7.2 and IL-12, which in turn enhances NKT cell activation and cytokine production. Propagation of this reaction involves the activation of NK cell cytolysis and IFN-y production, and, most importantly, the up-regulation of dendritic cells co stimulating properties and MHC class I- and MHC class 11- mediated antigen 20 presentation. Glycolipids, linked directly to a reporter group such as a fluorophore or other small molecule (e.g., biotin), have been proposed as probes for observing glycolipid association with CD1d and NKT cells (PCT patent application W02004/094444). In particular, fluorophore and biotin appended 6"amino 25 6"deoxy-galactosylceramide have been used to understand the roles of glycolipid structure in CD1d and NKT cell receptor binding. The staining allowed observation of the trafficking of glycolipids and the quantification of their association with CD1d and NKT cell receptors (Zhou et al., Org. Lett. 2000 4:1267-1270). Dansyl-, prodan derivative, and biotin-appended 6"-amino-6"-deoxy-galactosylceram ides were 30 found to stimulate NKT cells similarly to the parent glycolipid, suggesting that these compounds go through endocytosis, CD1d loading, presentation on the cell surface, and binding to T cell receptors causing T cell stimulation. However, Zhou et a/. appended small molecules to the glycolipid for labelling NKT cells and/or WO 2009/060086 PCT/EP2008/065179 3 CD1d restricted cells. It remains unknown if addition of larger molecules on the lipid chain would interfere with binding to CDd. Furthermore, glycolipids bound with antigens or drugs have not been reported so far. 5 Description of the invention Surprisingly, the inventors have found that a compound consisting of a glycolipid covalently bound to an antigen via a linker is able to trigger a specific immune response against the antigen stronger than the response observed when the glycolipid and the antigen are separately co-administered in a composition. 10 Not to be bound by theory, it is assumed that, upon the co-delivery of the antigen and the NKT agonist to the same APC, preferably the same B lymphocyte or the same DC, the B cell and/or DC becomes activated by the NKT cell and the antigen will therefore be presented to the conventional T cells by a fully activated B cell and/or DC. The proximity of an activated NKT may be useful when the APC 15 presents antigen to a T cell, since it will contribute to the cytokine environment. Additionally, when the glycolipid is covalently bound to a drug, the glycolipid enables for specific targeting of the drug to NKT cells. The present invention thus relates to compounds consisting of glycolipids covalently bound via a linker to an antigen or a drug, and to uses thereof. 20 Compound consisting of glycolpid covalently bound via a linker to an antigen or drug The compounds of the invention have Formula (1) xYz R1\ 0 0 0 R6 HN R2O R3 -10O ' R5 0 /O R4 25 wherein, WO 2009/060086 PCT/IEP2008/065179 4

R

1 , R 2 , R 3 , and R 4 are each independently hydrogen, C1-C 6 alkyl, C6-C12 aralkyl, or C-C 6 acyl ; and R 1 is either above or below the sugar ring.

R

6 is a) -(CH 2 )xCH3 where x is an integer selected from 1 to 100; or b) -(CH 2 )xCH=CH(CH 2 )yCH 3 or -(CH 2 )xCH=CH(CH 2 )yCH=CH(CH 2 )zCH 3 5 wherein x, y and z are integers independently selected from 1 to 14.

R

5 is one of the following formulae (11), (Ill) or (IV) 0R8 R7R7 (ll) lll)(IV) wherein R 8 is hydrogen, 0 1

-C

6 alkyl, C 6 -C1 2 aralkyl, or C-C 6 acyl, and 10 R7 is a linear or branched C 3

-C

100 alkyl; X is 0, N or S; Y is a cleavable or non-cleavable linker group; and Z is an antigen or a drug or a pharmaceutically acceptable salt thereof. As used herein, the term "alkyl" refers to a hydrocarbon chain that may be a 15 straight chain or branched chain, containing the indicated number of carbon atoms. For example, C-C 12 alkyl indicates that the group may have from I to 12 (inclusive) carbon atoms in it. The terms "arylalkyl" or "aralkyl" refer to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl and 9-fluorenyl groups. 20 The term "acyl" refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted by substituents. The term "cycloalkyl" as employed herein includes saturated cyclic, bicyclic, tricyclic, or polycyclic hydrocarbon groups having 3 to 12 carbons, wherein any 25 ring atom capable of substitution can be substituted by a substituent. Examples of cycloalkyl moieties include, but are not limited to, cyclohexyl and adamantyl. The term "aryl" refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system, wherein any ring atom capable of substitution can be substituted by a substituent. Examples of aryl moieties include, but are not limited 30 to, phenyl, naphthyl, and anthracenyl.

WO 2009/060086 PCT/EP2008/065179 5 The term "heterocyclyl" refers to a non-aromatic 3-10 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from 0, N, or S (e. g. , carbon 5 atoms and 1-3, 1-6, or 1-9 heteroatoms of N, 0, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom capable of substitution can be substituted by a substituent. The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 10 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from 0, N, or S (e. g. , carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, 0, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein any ring atom capable of substitution can be substituted by a substituent. 15 The term "oxo" refers to an oxygen atom, which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur. The term "substituents" refers to a group "substituted" on an alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl group at any atom of that group. 20 Suitable substituents include, without limitation, alkyl, alkenyl, alkynyl, alkoxy, halo, hydroxy, cyano, nitro, amino, SO 3 H, sulfate, phosphate, perfluoroalkyl, perfluoroalkoxy, methylenedioxy, ethylenedioxy, carboxyl, oxo, thioxo, imino alkyll, aryl, aralkyl), S(O)n alkyl (where n is 0-2), S(O)n aryl (where n is 0-2), S(O)n heteroaryl (where n is 0-2), S(O)n heterocyclyl (where n is 0- 2), amine (mono-, di-, 25 alkyl, cycloalkyl, aralkyl, heteroaralkyl, and combinations thereof), ester (alkyl, aralkyl, heteroaralkyl), amide (mono-, di-, alkyl, aralkyl, heteroaralkyl, and combinations thereof), sulfonamide (mono-, di-, alkyl, aralkyl, heteroaralkyl, and combinations thereof), unsubstituted aryl, unsubstituted heteroaryl, unsubstituted heterocyclyl, and unsubstituted cycloalkyl. 30 R 6 can have 1 to 100 methylene (CH 2 ) groups (i.e. R 6 is (CH 2 )xCH 3 and x=1-100). In particular R 6 may have 1-75 CH 2 groups, 1-50 CH 2 groups, 1-25 CH 2 groups, 1-20 CH 2 groups, 1-15 CH 2 groups, 1-10 CH 2 groups or 1-5 CH 2 groups. Preferably, R 6 has 15-25 CH 2 groups. More preferably, R 6 has 20-25 CH 2 groups.

WO 2009/060086 PCT/EP2008/065179 6 In certain embodiments R 6 contains 22 or 24 CH 2 groups (x=22 or x=24).

R

7 may be in particular a linear or branched C 3

-C

75 alkyl, C 3

-C

50 alkyl, C3

C

25 alkyl, C 3

-C

20 alkyl, C 3

-C

15 alkyl, C 10

-C

1 5 alkyl or C 3

-C

10 alkyl. In certain embodiments R 7 is an unbranched alkyl group of 14 carbon 5 atoms. Preferably R 6 is C 25

H

51 and R 7 is C 14

H

29 . More preferably, R 6 is C 23 H4 and

R

7 is C 14

H

29 . In another preferred embodiment, R 6 is C 23

H

4 7 and R 7 is C 14 H29. When R 1

-R

3 are other than hydrogen, preferably each are independently methyl, benzyl or acetyl. 10 According to an embodiment (referred thereafter as PBS-6), R1, R 2 , R 3 , R 4 and R 8 are hydrogen, R 5 is (1l), R 6 is C 2 5

H

51 , R 7 is C 14

H

29 and X is N. According to another embodiment (referred thereafter as PBS-57), R 1 , R 2 ,

R

3 , R 4 and R 8 are hydrogen, R 5 is (1l), R 6 is C 23

H

45 , R 7 is C 14

H

2 9 and X is N. According to still another embodiment (referred thereafter as PBS-14), R 1 , 15 R 2 , R 3 , R 4 and R 8 are hydrogen, R 5 is (11), R 6 is C 25

H

51 , R 7 is C 14

H

29 and X is N. In another embodiment (referred thereafter as PBS-96), R 1 , R 2 , R 3 , R 4 and

R

8 are hydrogen, R 5 is (11), R 6 is C 23

H

4 7 , R 7 is C 14

H

2 9 and X is N. Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic 20 acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, 25 lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful 30 as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e. g., magnesium), ammonium and N-(alkyl) 4 * salts. This invention also envisions the quaternization of WO 2009/060086 PCT/EP2008/065179 7 any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. Salt forms of the compounds of the formula herein can be amino acid salts of carboxy groups (e.g., L-arginine, -lysine, -histidine salts). 5 The glycolipid moiety of the compounds according to the invention described above may be synthesized as disclosed in the International patent application W02004/094444 which is incorporated herein by reference. Coupling of the linker-antigen or drug moiety (Y-Z) on the glycolipid moiety may be performed according to the method described in Zhou et al. (Org. Lett. 10 2000 4:1267-1270). An example of peptide antigen conjugation is displayed on the following scheme I: O 'oo0 HO SH O O4 N NA HO H OO HO NH HOHO HO HO Scheme I For obtaining such a peptide antigen conjugation, the peptide can be 15 dissolved at 50-100 pM in a suitable buffer at pH 7.0-7.5 at room temperature. Reduction of the disulfide bonds in the peptide can be carried out by adding a 10 fold molar excess of a reducing agent such as DTT or TCEP. The glycolipid containing the reactive group can be added dropwise to the peptide solution while stirring, to a final ratio of 10-20 moles of glycolipid for each mole of peptide. The 20 reaction can be allowed to proceed for 2 hours at room temperature or overnig ht at 4'C. The conjugate can finally be separated on a ge I filtration column. The linker group Y can be any carbon-containing chain or ring. For example, the linker can be -(CH 2 )t-, in which the chain optionally contains one or more terminal heteroatoms (e.g., N, 0, S), and/or one or more heteroatoms, rings, 25 double bonds, triple bonds that are inserted into the chain. The value of "t" can be 1-20, preferably 3-10.

WO 2009/060086 PCT/EP2008/065179 8 In a preferred embodiment of the present invention, the linker is composed of 6 carbons. Preferably, the linker contains a proteolytic cleavage site, in particular an endo-lysosomal protease cleavage site. Alternatively, the linker group contains a 5 lipase cleavage site. In particular, the linker group may contain a protease cleavage site and/or a lipase cleavage site. Preferably, the compound according to the present invention is capable of binding a CDId monomer or tetramer. More preferably, this compound is able to activate an NKT cell. 10 As used herein, an "antigen" refers to any substance or material that is specifically recognized by a binding entity of the immune system, such as an antibody or antibody fragment comprising the paratope or a T cell receptor (TCR). Suitably, antigens of the compound of Formula (1) are derived from attenuated or killed infectious agents. Whole microorganisms or portions thereof 15 (e.g., membrane ghosts; crude membrane preparations, lysates and other preparations of microorganisms) may be used. Suitable infectious agents from which an antigen may be derived include, but are not limited to, pathogens and microorganisms such as bacteria, parasites and viruses. In some contexts, suitable antigens are obtained or derived from a viral pathogen that is associated 20 with human disease including, but not limited to, HIV/AIDS (Retroviridae, e.g., gp120 molecules for HIV-1 and HIV-2 isolates, HTLV-1, HTLV-11), influenza viruses (Orthomyxoviridae, e.g., types A, B and C), herpes (e.g., herpes simplex viruses, HSV-1 and HSV-2 glycoproteins gB, gD and gH), rotavirus infections (Reoviridae), respiratory infections (parainfluenza and respiratory syncytial 25 viruses), Poliomyelitis' (Picornaviridae, e.g., polloviruses, rhinoviruses), measles and mumps (Paramyxoviridae), Rubella (Togaviridae, e.g., rubella virus), hepatitis (e.g., hepatitis viruses types A, B, C, D, E and/or G), cytomegalovirus (e.g., gB and gH), gastroenteritis (Caliciviridae), Yellow and West Nile fever (Flaviviridae), Rabies (Rhabdoviridae), Korean hemorrhagic fever (Bunyaviridae), Venezuelan 30 fever (Arenaviridae), warts (Papillomavirus), simian immunodeficiency virus, encephalitis virus, varicella zoster virus, Epstein-Barr virus, and other virus families, including Coronaviridae, Bimaviridae and Filoviridae.

WO 2009/060086 PCT/EP2008/065179 9 Suitable bacterial and parasitic antigens can also be obtained or derived from known agents responsible for diseases including, but not limited to, diphtheria, pertussis, tetanus, tuberculosis, bacterial or fungal pneumonia, otitis media, gonorrhea, cholera, typhoid, meningitis, mononucleosis, plague, shigellosis 5 or salmonellosis, Legionnaires' disease, Lyme disease, leprosy, malaria, hookworm, Onchocerciasis, Schistosomiasis, Trypanosomiasis, Leishmaniasis, giardiases, amoebiasis, filariasis, Borrelia, and trichinosis. Still further antigens can be obtained or derived from unconventional pathogens such as the causative agents of kuru, Creutzfeldt-Jakob disease (CJD), scrapie, transmissible mink 10 encephalopathy, and chronic wasting diseases, or from proteinaceous infectious particles such as prions that are associated with mad cow disease. Additional specific pathogens from which antigens can be derived include Mycobacterium tuberculosis, Chlamydia, Neisseria gonorrhoeae, Shigella, Salmonella, Vibrio cholerae, Treponema pallidum, Pseudomonas, Bordetella 15 pertussis, Brucella, Francisella tularensis, Helicobacter pylori, Leptospira interrogans, Legionella pneumophila, Yersinia pestis, Streptococcus (types A and B), pneumococcus, meningococcus, Haemophilus influenza (type b), Toxoplasma gondii, Moraxella catarrhalis, donovanosis , and actinomycosis; fungal pathogens include candidiasis and aspergillosis; parasitic pathogens include Taenia, flukes, 20 roundworms, amebiasis, giardiasis, Cryptosporidium, Schistosoma, Pneumocystis carinii, trichomoniasis and trichinosis. The present invention can also be used to provide a suitable immune response against numerous veterinary diseases, such as foot-and-mouth diseases, coronavirus, Pasteurella multocida, Helicobacter, Strongylus vulgaris, Actinobacillus pleuropneumonia, Bovine Viral Diarrhea Virus 25 (BVDV), Klebsiella pneumoniae, Escherichia coli, and Bordetella pertussis, parapertussis and brochiseptica. In other embodiments, antigens for binding to glycolipids that may be used are tumor-derived antigens or autologous or allogeneic whole tumor cells. Suitably, the tumor antigen is a tumor specific antigen (TSA) or a tumor associated 30 antigen (TAA). Several tumor antigens and their expression patterns are known in the art and can be selected based on the tumor type to be treated. Non-limiting examples of tumor antigens include cdk4 (melanoma), P-catenin (melanoma), caspase-8 (squamous cell carcinoma), MAGE-1 and MAGE-3 (melanoma, breast, WO 2009/060086 PCT/EP2008/065179 10 glioma), tyrosinase (melanoma), surface Ig idiotype (e.g., BCR) (lymphoma), Her 2/neu (breast, ovarian), MUC-1 (breast, pancreatic) and HPV E6 and E7 (cervical carcinoma). Additional suitable tumor antigens include prostate specific antigen (PSA), sialyl Tn (STn), heat shock proteins and associated tumor peptides (e.g., 5 gp96), ganglioside molecules (e.g., GM2, GD2, and GD3), carcinoembryonic antigen (CEA) and MART-1. According to another embodiment, a drug is appended to the glycolipid. Examples of suitable drugs include cyclosporine, FK 506, and rapamycin 10 Vaccine and pharmaceutical compositions Another aspect of this invention relates to a vaccine composition that comprises a compound of Formula (1) as defined above wherein Z is an antigen. "Vaccine" refers to a composition which, when administered to a subject, induces cellular and/or humoral immune responses as described herein. 15 In the context of the invention, "subject" refers to an animal, preferably a non-human or human mammal. Examples of non-human mammals include rodents and primates. Most preferably, a subject is human. The invention also provides a method of inducing, in particular stimulating, an immune response in a subject which comprises administering the subject with 20 said compound or vaccine composition according to the invention. In the context of the invention, "stimulating an immune response" refers to reinforcing an immune response which has been induced by the presence of an antigen. In a preferred embodiment, the immune response is a humoral immune 25 response. As used herein, a "humoral immune response" is the production of antibodies by B cells, and the accessory process that accompanies it, including, but not limited to, e.g., Th2 activation and cytokine production, germinal center formation and isotype switching, affinity maturation production and memory cell generation. For purposes of determining whether a humoral immune response is 30 stimulated, a quantitative comparison of the signal in a sample from a subject vaccinated with the compound or vaccine composition defined above can be compared to a sample from a subject vaccinated with antigen alone. The humoral immune response may be evaluated by measuring the effector functions of WO 2009/060086 PCT/EP2008/065179 11 antibodies, including pathogen or toxin neutralization, classical complement activation, and opsosin promotion of phagocytosin and pathogen elimination. The antibodies produced in response to administering the compound or vaccine composition defined above and an antigen may be of any type, e.g., IgM, IgA, or 5 IgG. The humoral immune response may be assayed by any quantitative method known in the art, e.g., ELISA, single radial immunodiffusion assay (SRID), enzyme immunoassay (EIA), or hemagglutination inhibition assay (HAI). In another preferred embodiment, the stimulation of an immune response corresponds to activation of CD4+ T lymphocytes. As understood in the art, CD4+ 10 T cells, or "T helper cells," are cells that recognize antigens presented by class 11 major histocompatability marker (MHC) on the surface of antigen presenting cells, and secrete lymphokines to stimulate both cell-mediated and antibody-mediated branches of the immune system. CD4+ T cell activation promotes lymphokine secretion, immunoglobulin isotype switching, affinity maturation of the antibody 15 response, macrophage activation and enhanced activity of natural killer (NK) and cytotoxic T cells (CTL). Lymphokines are proteins secreted by lymphocytes that affect their own activity and/or the activity of other cells. Lymphokines include, but are not limited to, interleukins and cytokines, e.g., IL-2, IL-4, IL-5, IL-6, IL-10, IL 12, or INFy. For purposes of determining whether a CD4+ T lyphocytes are 20 activated, a quantitative comparison of the signal in a sample from a subject vaccinated with the compound or vaccine composition as defined above can be compared to a sample from a subject vaccinated with antigen alone. Methods to assay activation CD4+ T cells are known in the art. In another preferred embodiment, the stimulation of an immune response 25 corresponds to activation of CD8+ T lymphocytes. CD8+ T lymphocytes recognize antigens presented by Class I MHC molecules (present on all nucleated cells). Engagement of the MHC class-I peptide complex results in delivery of lytic granules to the target cell causing lysis of the target cell. Methods used to assay the activation of CD8+ T cells are known in the art, and induce but are not limited 30 to ELISPOT, ELISA, and cytotoxic assays. Alternatively, a mouse model may be used to monitor the activation of CD8+ T cells using a fluorescent assay to measure cell-mediated cytotoxicity, as described in Hermans et al. (2004) J. Immunol. Meth. 285:25-40.

WO 2009/060086 PCT/EP2008/065179 12 Suitable effective dosage amounts of the compound of Formula (I) in vaccine compositions may be determined by those of skill in the art, but typically range from about 1 microgram to about 10,000 micrograms per kilogram of body weight, although they are typically about 1,000 micrograms or less per kilogram of 5 body weight. In some embodiments, the effective dosage amount ranges from about 10 to about 5,000 micrograms per kilogram of body weight. In another embodiment, the effective dosage amount ranges from about 50 to about 1,000 micrograms per kilogram of body weight. In another embodiment, the effective dosage amount ranges from about 75 to about 500 micrograms per kilogram of 10 body weight. The composition can be administered in a single dose, or split into multiple doses over a period of weeks or months. It will be appreciated that the dosage of antigen will depend on the specific antigen, and on the age and immune status of the subject, as well as other relevant factors that may be determined by those skilled in the art. 15 Administration of a vaccine of the invention may suitably result in therapeutic or prophylactic treatment of an infectious disease or a disease related to an infectious agent. "Treating" or "treatment" of an infectious disease includes one or more of: (1) inhibiting infection, i.e. preventing the infectious agent from establishing an infection, (2) preventing spread of the infectious agent, i.e. to other 20 areas of the subject, or from one subject to another, (3) limiting disease severity, (4) preventing recurrent infections, i.e. limiting reactivation of latent or persistent infections, and (5) palliating symptoms of the infectious disease. Another aspect of this invention relates to a pharmaceutical composition that contains a compound of Formula (I) wherein Z is a drug. 25 The invention also provides a method of treatment of a subject in need thereof which comprises administering said subject with said compound or pharmaceutical composition. "An effective amount" refers to an amount of a compound that confers a therapeutic effect on the treated subject. The therapeutic effect may be objective 30 (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.01 pg/Kg to about 500 pg/Kg, alternatively from about 0.1 to about 100 pg/Kg, alternatively from about 1 to about 50 pg/Kg.

WO 2009/060086 PCT/EP2008/065179 13 Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. As appreciated by skilled artisans, vaccines are suitably formulated to be compatible with the intended route of administration. Examples of suitable routes 5 of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, intramuscular, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Preferably, the vaccines according to the invention may be administered intramuscularly, intravenously, subcutaneously, intradermally, intraperitinatally, 10 intranasally, enterally or by inhalation. Most preferably, the vaccines according to the invention are administered intramuscularly or subcutaneously. The vaccine may also include a physiologically acceptable vehicle. A "physiologically acceptable" vehicle is any vehicle that is suitable for in vivo administration (e.g., oral, transdermal or parenteral administration) or in vitro use, 15 i.e., cell culture. Suitable physiologically acceptable vehicles for in vivo administration include water, buffered solutions and glucose solutions, among others. Additional components of the compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers or lubricants, in addition to the physiologically acceptable vehicle. In particular, suitable excipients include, but 20 are not limited to, Tween 20, DMSO, sucrose, L-histadine, polysorbate 20 and serum. The compounds of the formula described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously ; or orally, buccally, nasally, 25 transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 pg/kg of body weight, alternatively dosages between 1 mg and 1000mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to 30 achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined WO 2009/060086 PCT/IEP2008/065179 14 with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active 5 compound. Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of 10 excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician. Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if 15 necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms. 20 The compositions delineated herein include the compounds of the formula delineated herein, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein. The term "pharmaceutically acceptable carrier" refers to a carrier that may 25 be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is non-toxic when administered in doses sufficient to deliver a therapeutic amount of the compound. Pharmaceutically acceptable carriers and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion 30 exchangers, alumina, aluminium stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer WO 2009/060086 PCT/EP2008/065179 15 substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, 5 polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcell ulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, p-, and y- cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2-and 3-hydroxypropyl-p-cyclodextrins, or 10 other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formula described herein. The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or 15 administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein 20 includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous 25 suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or 30 solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, WO 2009/060086 PCT/EP2008/065179 16 any bland fixed oil may be employed including synthetic mono-or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil 5 solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and/or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability 10 enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, 15 capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried 20 corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavouring and/or colouring agents may be added. 25 The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active 30 components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols. Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible WO 2009/060086 PCT/EP2008/065179 17 by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid 5 petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan 10 monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention. 15 The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, 20 and/or other solubilizing or dispersing agents known in the art. A composition having the compound of the formula herein can be administered using an implantable device. Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous or timed-release delivery of 25 compounds or compositions delineated herein is desired. Additionally, the implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs) (see Negrin et al.,(2001) Biomaterials, 22 (6): 563). Timed-release technology involving alternate delivery methods can also be 30 used in this invention. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.

WO 2009/060086 PCT/EP2008/065179 18 Also within the invention is a patch to deliver active chemotherapeutic compounds herein. A patch includes a material layer (e.g., polymeric, cloth, gauze, bandage) and the compound of the formula herein as delineated herein. One side of the material layer can have a protective layer adhered to it to resist passage of 5 the compounds or compositions. The patch can additionally include an adhesive to hold the patch in place on a subject. An adhesive is a composition, including those of either natural or synthetic origin, that when contacted with the skin of a subject, temporarily adheres to the skin. It can be water resistant. The adhesive can be placed on the patch to hold it in contact with the skin of the subject for an extended 10 period of time. The adhesive can be made of a tackiness, or adhesive strength, such that it holds the device in place subject to incidental contact, however, upon an affirmative act (e.g., ripping, peeling, or other intentional removal) the adhesive gives way to the external pressure placed on the device or the adhesive itself, and allows for breaking of the adhesion contact. The adhesive can be pressure 15 sensitive, that is, it can allow for positioning of the adhesive (and the device to be adhered to the skin) against the skin by the application of pressure (e.g., pushing, rubbing) on the adhesive or device. Brief description of the drawings 20 Figure 1 shows the detection of SIINFEKL-specific cytolytic activity in blood of immunized mice. All samples have been collected the day after target cells injection. The mice were immunized by intravenous route with 100 pg of Ova peptide alone (group 1), 1 pg of Ova peptide alone (group 2), a combination of 100 25 pg of Ova peptide and 1 pg of glycolipid (group 3), a combination of 1 pg of Ova peptide and 1 pg of glycolipid (group 4), 1 pg of Ova peptide covalently linked to glycolipid (group 5), 100 ng of Ova peptide covalently linked to glycolipid (group 6) or 10 ng of Ova peptide covalently linked to glycolipid (group 7). 30 Figure 2 shows histograms representing the percentage of SIINFEKL-H2Kb specific CD8+ (CD8+ SIINFEKL Pentamer + (%), abscissa) in the blood from mice immunized with PBS (PBS), ovalbumin peptide (OVA), ovalbumin peptide covalently linked to PBS-6 (PBS6-OVA), ovalbumin peptide covalently linked to WO 2009/060086 PCT/EP2008/065179 19 PBS-14 (PBS14-OVA), or ovalbumin peptide covalently linked to PBS-57 (PBS57 OVA). Figure 3 shows histograms representing the percentage of SIINFEKL specific 5 cytolytic activity (% specific lysis, abscissa) in the blood from mice immunized with PBS (PBS), short ovalbumin peptide (50 pg short OVA), long ovalbumin peptide (50 pg long OVA), ovalbumin peptide covalently linked to PBS-6 (1 pg PBS6 OVA), ovalbumin peptide covalently linked to PBS-14 (1 pg PBS14-OVA), or ovalbumin peptide covalently linked to PBS-57 (1 pg PBS57-OVA). 10 Figure 4 shows histograms representing the titer of OVA specific IgG1 antibodies in the blood from mice immunized with ovalbumin with CFA/IFA (positive control, CTRL+), short ovalbumin peptide (50 pg short OVA), long ovalbumin peptide (50 pg long OVA), ovalbumin peptide covalently linked to PBS-6 (1 pg PBS6-OVA), 15 ovalbumin peptide covalently linked to PBS-14 (1 pg PBS14-OVA), or ovalbumin peptide covalently linked to PBS-57 (1 pg PBS57-OVA). Figure 5 shows histograms representing the titer of OVA specific IgG2a antibodies in the blood from mice immunized with ovalbumin with CFAllFA (positive control, 20 CTRL+), short ovalbumin peptide (50 pg short OVA), long ovalbumin peptide (50 pg long OVA), ovalbumin peptide covalently linked to PBS-6 (1 pg PBS6-OVA), ovalbumin peptide covalently linked to PBS-14 (1 pg PBS14-OVA), or ovalbumin peptide covalently linked to PBS-57 (1 pg PBS57-OVA). 25 Figure 6 shows histograms representing the percentage of Trp2 specific cytolytic activity (% specific lysis, abscissa) in the blood from mice immunized with PBS (PBS), short Trp2 peptide (50 pg short Trp2), long Trp2 peptide (50 pg long Trp2), Trp2 peptide covalently linked to PBS-6 (1 pg PBS6-Trp2), Trp2 peptide covalently linked to PBS-14 (1 pg PBS14-Trp2), or Trp2 peptide covalently linked to PBS-57 30 (1 pg PBS57-Trp2). Examples WO 2009/060086 PCT/EP2008/065179 20 Example 1: Test immunization induced with antigen linked with PBS6 administrated by intravenous route in VITAL assay. 5 -Material Thirty-three 8 week-old C57B1/6J CD45.2 female mice were used for immunisation. They were split into 8 groups: groups 1, 2, 4, 6 and 8 included 3 animals and groups 3, 5 and 7 included 6 animals. Twenty 8 week-old C57B11/6J CD45.2 female mice were used for target cells. 10 -Target cells for in vivo cytotoxicity assay The in vivo cytotoxicity of the ovalbumine peptide of sequence SIlNFEKL (SEQ ID NO:1) (or Ova peptide) induced CD8+ T cell response was evaluated by VITAL assay as described by Hermans et al (2004, J. Immunol. Methods, 285:25-40). 15 Briefly, congenic splenocyte populations were labelled with the fluorescent dye CFSE with either low concentration (0.6 pM during 10 min at 37'C) or high concentration (6 pM during 10 min at 37C). Population labelled with high concentration of CFSE was pre-loaded with SIINFEKL peptide (5 pM during 60 min at 37'C) whereas population labelled with low concentration of CFSE was pre 20 loaded with irrelevant LCMV gp33-41 peptide (5 pM during 60 min at 37C). Equal numbers of both populations were mixed and injected by intra-venous route into immunized mice. 10.106 cells of each condition (total of 20.106 cells) in a volume of 100 pl were injected into the orbital sinus or into the lateral vein tail of each immunized mouse, 10 days after vaccination. 25 -Treatment of vaccination The ovalbumine peptide consists in the SIINFEKL sequence (SEQ ID NO:1) (i.e. amino-acids 257-264 of ovalbumine) and the glycolipid used is PBS-6. The mice were vaccinated by intravenous route at day 0 with 50 pl of the following 30 solutions according to the different groups: 1- 100 pg of Ova peptide into 50 pl of PBS 2- 1 pg of Ova peptide into 50 pl of PBS 3- 100 pg of Ova peptide combined with 1 pg of PBS-6 into 50 pl of PBS WO 2009/060086 PCT/EP2008/065179 21 4- 1 pg of Ova peptide combined with 1 pg of PBS-6 into 50 pl of PBS 5- 1 pg of Ova peptide covalently linked to PBS-6 into 50 pl of PBS 6- 100 ng of Ova peptide covalently linked to PBS-6 into 50 pl of PBS 7- 10 ng of Ova peptide covalently linked to PBS-6 into 50 pl of PBS 5 -Read out Specific lysis of the SINFEKL-loaded targets was monitored by FACS analysis into peripheral blood cells or splenocytes. Blood samples have been collected into orbital sinus and spleens have been collected after immune mice sacrifice by day 10 11. The mean percent survival of peptide-pulsed targets was calculated relative to that of the control population, and cytotoxic activity was expressed as percent specific lysis (100 minus the mean percent survival of peptide-pulsed targets). -Results 15 The aim of this study was to evaluate a covalent linkage of peptide with glycolipid NKT agonist to induce specific lysis response when it was administrated by intravenous route, compared to the same peptide mixed with the same glycolipid. Mice treated with 1 pg to 100 pg of Ova peptide alone presented no antigen specific lysis. Baseline of natural lysis in placebo control was evaluated between 20 6% and +3% (Figure 1). Results in mice treated with 100 pg of Ova peptide in combination with 1 pg of PBS6 by intravenous route presented strong specific lysis in all mice as expected. Mice treated with 1 pg of Ova peptide in combination with 1 pg of PBS-6 did not present any specific lysis after immunization by intravenous route. However, results in mice treated with 1 pg of Ova peptide covalently linked 25 to PBS-6 presented strong specific lysis in all mice. This activity was still present at 100 and 10 ng. This result suggested that immunization by intravenous route with covalently linked antigenic peptide gave better result than the injection of the mixture. In conclusion this experiment suggested that this linkage between antigen and 30 CD1d restricted adjuvant increase the potency of the response.

WO 2009/060086 PCT/EP2008/065179 22 Example 2: Evaluation of the stimulation of the immune response induced by Qlycolipid adjuvant using the model antigen OVA. -Material 5 Forty-eight 9 week-oldC57Bl/6J CD45.2 female mice were used for immunisation. They were split into 9 groups: groups 1 and 2 included 3 animals and groups 3 to 9 included six animals. -Treatment of vaccination: 10 The ovalbumin peptide consists in the VSGLEQLESIINFEKLTEWTS sequence (SEQ ID NO:2) and the glycolipids used are PBS-6, PBS-14 and PBS-57. The mice were vaccinated by intramuscular route at day 0 and 14 with the following solutions according to the different groups: - Group 1: 100 pl of PBS; 15 - Group 2: 50 pg of Ova into 100 pl of PBS; - Group 3: 1 pg of Ova-PBS-6 into 100 pl of PBS; - Group 4: 1 pg of Ova-PBS-14 into 100 pl of PBS; - Group 5: 1 pg of Ova-PBS-57 into 100 pl of PBS. 20 -Read out: Detection of SIINFEKL specific CD8+ cells was monitored by FACS following H 2Kb SIINFEKL pentamer and CD8 co-staining. Cytokine response was monitored in the spleen by CBA analysis. Cytokine secretion was monitored with the Mouse Th1/Th2 cytokine CBA on Flow 25 cytometer, and cytokine concentration determined using the FCAP Array software, BD. -Results The aim of this study was to evaluate the efficacy of the linkage between an 30 antigen and a glycolipid to induce specific immune responses when it was administered by intramuscular route.

WO 2009/060086 PCT/IEP2008/065179 23 Mice treated with 1 pg of OVA covalently linked to either PBS-6, PBS-14 or PBS 57, presented a stronger percentage of SIINFEKL-H2Kb specific CD8* in the blood than mice treated with 50 pg of OVA alone (Figure 2). Accordingly, this experiment demonstrates that the linkage between antigen and 5 glycolipid adjuvants increase the potency of the response. Example 3: Test immunization induced with antigen linked with different glycolipid adjuvants administrated by intramuscular route. 10 -Material Sixty-nine 9 week-old C57BI/6J CD45.2 female mice were used for immunisation. They were split into 14 groups: groups 1 to 5 included 3 animals, and groups 6 to 14 included 6 animals. 15 -Target cells for in vivo cytotoxicity assay The in vivo cytotoxicity of SIINFEKL (SEQ ID NO:1) induced CD8* T cell response was evaluated by VITAL assay as described in Example 1. 20 -Treatment of vaccination The short ovalbumin peptide consists in the SIINFEKL sequence (SEQ ID NO:1; amino acids 257 to 264 of ovalbumin), the long ovalbumin peptide consists in the VSGLEQLESIINFEKLTEWTS sequence (SEQ ID NO:2; amino acids 250 to 269 of ovalbumin) and the glycolipids used are PBS-6, PBS-14 and PBS-57. 25 The mice were vaccinated by intramuscular route at day 0 with the following solutions according to the different groups: - Group 1: 50 pl of PBS; - Group 2: 50 pg of Short OVA into 50 pl of PBS/DMSO; - Group 3: 50 pg of Long OVA into 50 pl of PBS/DMSO 30 - Group 4: 1 pg of PBS-6-OVA into 50 pl of PBS; - Group 5: 1 pg of PBS-57-OVA into 50 pl of PBS; - Group 6: 1 pg of PBS-14-OVA into 50 pl of PBS.

WO 2009/060086 PCT/EP2008/065179 24 -Read out: The read out was as described in Example 1. -Results 5 The aim of this study was to evaluate a covalent linkage of peptide with glycolipid NKT agonist to induce specific lysis response when it was administrated by intramuscular route, compared to the same peptide alone. Mice treated with 1 pg of OVA covalently linked to either PBS-6, PBS-14 or PBS 57, presented a stronger percentage of SIINFEKL- specific cytolytic activity in the 10 blood than mice treated with 50 pg of OVA alone (Figure 3). Accordingly, this experiment demonstrates that the linkage between antigen and glycolipid adjuvants increase the potency of the response. 15 Example 4: Evaluation of specific antibody response against ovalbumin peptide. The aim of this study was to evaluate IgG1 and IgG2a antibody response following immunization with ovalbumin in combination with different adjuvant covalently 20 linked. -Material and methods The sera tested were as follows: Group 1; 6 mice immunized with 500 pg of ova protein with CFA/IFA (Positive 25 control) Group 2: 6 mice immunized with 50 pg of long ova peptide of sequence ISSAESLKISQAVHAAHAEINEA (SEQ ID NO:3; amino acids 316 to 338 of ovalbumin) Group 3: 6 mice immunized with 50 pg of short ova peptide of sequence 30 KISQAVHAAHA (SEQ ID NO:4; amino acids 323 to 333 of ovalbumin) Group 4: 6 mice immunized with 1 pg PBS-6-OVA Group 5: 6 mice immunized with 1 pg PBS-14-OVA Group 6: 6 mice immunized with I pg PBS-57-OVA WO 2009/060086 PCT/EP2008/065179 25 All mice were immunized by intramuscular route at day 0 and day 14. All samples were collected 14 days following the second immunization and the IgGI and IgG2a titers specific of ovalbumin were evaluated. 5 -Results Mice treated with 1 pg of OVA covalently linked to either PBS-6, PBS-14 or PBS 57, presented higher titers of both IgGI (Figure 4) and IgG2a (Figure 5) specific of ovalbumin than mice treated with 50 pg of OVA alone. 10 Accordingly, this experiment demonstrates that the linkage between antigen and glycolipid adjuvants increase the potency of the response. Example 5: Test immunization induced with tyrosinase-related protein 2 15 (Trp2) antigen linked with different glycolipid adiuvants administrated by intramuscular route -Material Sixty-nine 9 week-old C57B1/6J CD45.2 female mice were used for immunisation. 20 They were split into14 groups: groups I to 5 included 3 animals, and groups 6 to 14 included 6 animals. -Target cells for in vivo cytotoxicity assay The in vivo cytotoxicity of Trp2 181_188 induced CD8* T cell response was 25 evaluated by VITAL assay as described in Example 1. -Treatment of vaccination The Trp2 short peptide consists in the sequence of amino acids 181 to 188 of Trp2, the Trp2 long peptide consists in the sequence of amino acids 174 to 193 of 30 Trp2 and the glycolipids used are PBS-6, PBS-14 and PBS-57. The mice were vaccinated by intramuscular route at day 0 with the following solutions according to the different groups: - Group 1: 50 pl of PBS; WO 2009/060086 PCT/EP2008/065179 26 - Group 2: 50 pg of Trp2 short peptide into 50 pl of PBS/DMSO; - Group 3: 50 pg of Trp2 long peptide into 50 pl of PBS/DMSO - Group 4: 1 pg of PBS-6-Trp2 into 50 pl of PBS; - Group 5: 1 pg of PBS-57-Trp2 into 50 pl of PBS; 5 - Group 6: 1 pg of PBS-14-Trp2 into 50 pl of PBS. -Read out: The read out was as described in Example 1. 10 -Results The aim of this study was to evaluate a covalent linkage of a different antigen with glycolipid NKT agonists to induce specific lysis response when it was administrated by intramuscular route, compared to the same antigen alone. Mice treated with I pg of Trp2 covalently linked to either PBS-6, PBS-14 or PBS 15 57, presented a stronger percentage of Trp2-specific cytolytic activity in the blood than mice treated with 50 pg of Trp2 alone (Figure 6). Accordingly, this experiment demonstrates that the results obtained with the ovalbumin peptide covalently linked to glycolipid adjuvants are also observed with other antigens. 20 H:\aar\Intenvoven\NRPortbl\DCC\AAR\5053074_1.DOC-1A)4/2013 26a Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or method step or group of elements or integers or method steps but not the exclusion of any element or integer or method step or group of elements or integers or method steps. Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

Claims (19)

1. A compound having Formula (1): R1\ 0 0 O 0 R6 OHN(I R2 R3 0 0 R5 0 R4 wherein, R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, C1-C6 alkyl, C6-C12 aralkyl, or C1-C6 acyl ; and R 1 is either above or below the sugar ring. R 6 is a) -(CH 2 )xCH 3 where x is an integer selected from 1 to 100; or b) -(CH 2 )xCH=CH(CH 2 )yCH 3 or -(CH 2 )xCH=CH(CH 2 )yCH=CH(CH 2 )zCH 3 wherein x, y and z are integers independently selected from 1 to 14. R 5 is one of the following formulae (II), (111) or (IV) 0R8 R7 ,R7 R7 (l)(1ll) (IV), wherein R 8 is hydrogen, C1-C6 alkyl, C6-C12 aralkyl, or C1-C6 acyl, and R 7 is a linear or branched C3-C100 alkyl; X is-O, N or S; Y is a cleavable or non-cleavable linker group; and Z is an infectious agent or a tumor antigen or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1, wherein R 1 , R 2 , R 3 , R 4 and R 8 are hydrogen, R 5 is (II), R 6 is C 25 H 5 1 , R 7 is C 14 H 29 and X is N. H:\arluntenvoven\NRPobI\DCC\AAR\5053064_ .DOC-8/04/2013 28

3. The compound of Claim 1, wherein R 1 , R 2 , R 3 , R 4 and R 8 are hydrogen, R5 is (II), R 6 is C 2 3 H 45 , R 7 is C 14 H 2 9 and X is N.

4. The compound of Claim 1, wherein R 1 , R 2 , R 3 , R 4 and R 8 are hydrogen, R5 is (II), R 6 is C 2 3 H 47 , R 7 is C 14 H 2 9 and X is N.

5. The compound according to any one of Claims 1 to 4, wherein the linker contains a protease cleavage site.

6. The compound according to any one of Claims 1 to 4, wherein the linker contains a lipase cleavage site.

7. The compound according to any one of Claims 1 to 4, wherein the linker contains a protease cleavage site and/or a lipase cleavage site.

8. The compound according to any one of Claims 1 to 7, wherein compound is capable of activating an NKT cell.

9. A vaccine composition comprising the compound of any one of Claims 1 to 8 and a physiologically acceptable vehicle.

10. A pharmaceutical composition comprising the compound of any one of Claims 1 to 8 and a physiologically acceptable vehicle.

11. A method of stimulating an immune response in a subject comprising administering to the subject an effective amount of a vaccine composition according to Claim 9.

12. Method according to Claim 11, wherein the immune response is a humoral immune response. H:\aar\TIntrwovcn\NRPorlbl\DCC\AAR\5053064_ l.DOC-S/04/2013 29

13. Method according to Claim 11, for activating CD4+ T lymphocytes.

14. Method according to Claim 11, for activating CD8+ T lymphocytes.

15. A method of treating a subject having a tumor or an infectious disease wherein said method comprises administering to the subject an effective amount of the composition of Claim 10.

16. A compound according to any one of Claims 1 to 8 substantially as herein described with reference to the Figures and/or Examples.

17. A vaccine composition according to Claim 9 substantially as herein described with reference to the Figures and/or Examples.

18. A pharmaceutical composition according to Claim 10 substantially as herein described with reference to the Figures and/or Examples.

19. a method according to any one of Claims 11 to 15 substantially as herein described with reference to the Figures and/or Examples.